on Vitreomacular Interface Abnormalities in Diabetic RetinopathyNCT03686436
Vitreomacular Interface Abnormalities in Diabetic Retinopathy Using OCT
An observational study of on Vitreomacular Interface Abnormalities in Diabetic Retinopathy, run by Assiut University.
Trial summary
to evaluate vitreomacular interface abnormalities in diabetic retinopathy by using Ocular Coherence Tomography (OCT) Read more about this study
- Who is it for?
- Ages 12 to 70 years
- Conditions the study is for
- on Vitreomacular Interface Abnormalities in Diabetic Retinopathy
- What is being tested?
- ocular coherence tomography
- Type of treatment
- Medical device
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Feb 2019to 1 Mar 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 70 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: diabetic male and female patient with age between 12 and 70 years who live in Asiut city
Who may be able to join
- diabetic patient with or without treatment and with or without evidence of vitreomacular traction on clinical examination
Who cannot join
- diabetic patient with unclear media as dense cataract,
- vitreous Hemorrhage and corneal opacity
Trial locations and contacts
No sites are listed yet.
sharaf mohamed contact
About this study
Official title: Vitreomacular Interface Abnormalities Indiabetic Retinopathy Using Ocular Coherence Tomography
to evaluate vitreomacular interface abnormalities in diabetic retinopathy by using Ocular Coherence Tomography (OCT)
Read the detailed description
Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness .DR can be complicated by scar tissue formation, macular edema tractional retinal detachment. Optical coherence tomography has found patient with DR has diffuse retinal thickening , cystoid macular edema ,posterior hayaloid traction ,tractional retinal detachment.
The VMI in patient with DR can influence the emergence ,progression ,and treatment of DR.
The role of posterior hyaloid and vitreous on viteromacular interface abnormalities The anomalous separation of vitreous cortex from ILM can lead to abnormal vitreomacular interface. This separation can happen when liquefaction occur faster than detachment of the vitreous cortex or when an abnormal adhesion of the vitreous cortex to the ILM occur.
The VMI abnormalities in DR include I. Vitreomacular adhesion The International Vitreomacular Traction Study group has defined the vitremacular adhesion as specific stage of vitreous separation when partial detachment of the vitreous in perifoveal area has occurred without any abnormalities to the retinal contour.
II. Vitreomacular traction There is abnormal vitreous adhesion, there can be excessive traction on the macula from the vitreous that change the contour of foveal surface. By OCT any distortion of foveal contour together with partial posterior vitreous detachment is considered vitreomacular traction . In accordance with the International Vitreomacular Traction Study Group definition vitreomacular traction can be classified as focal or broad based on horizontal area of adhesion.
III. Cystoid macular edema The vitreous has been implicated as a cause of macular edema via mechanical and physiologic mechanisms.One of the most constructive hypothesis on how vitreomacular traction may result in macular edema was given by Schubert in 1989,and was summarized by Bringmann and Wiedmann Vitro retinal traction can also exert forces at the level of retinal pigment epithelium ,which can eventually result in morphological retinal pigment epithelial changes .
IV. Epiretinal membrane The epiretinal membrane is a cellular proliferation that creates a semi translucent, fibrocellular proliferation on the surface of the inner retina. Because epiretinal membrane contain contractile cellular elements they can be associated with retinal folding and macular thickening thereby leading to decreased visual acuity, metamorphopsia, monocular diplopia .
- Full thickness hole Is a full thickness defect in the fovea, include the complete interruption of all retinal layers from the ILM to the retinal pigment epithelium. antero posterior traction, secondary to abnormal attachment at the fovea, and tangential contraction of the perifoveal vitreous cortex may be responsible for the development of the macular hole.
VI. Lamellar holes These include an irregular foveal contour, a defect or break in the inner fovea, a splitting of the inner and outer retina , lack of a full thickness foveal defect, and intact photo receptors.
VII. Macular pseudo hole By OCT the pseudo hole has no loss of retinal tissue. They have invaginated or heaped foveal edge, an epiretinal membrane with a central opening ,and a steep macular contour to the central fovea .the steep foveal contour creates the appearance of hole, even though there is no loss of retinal tissue.
Aim of work Primary outcome : To evaluate the changes in vitreomacular interface in diabetic retinopathy by using Spectral Domain Ocular Coherence Tomography ( SD OCT) Secondary outcome : To evaluate other macular changes in Spectral Domain Ocular Coherence Tomography ( SD OCT) in diabetic patient with vitreomacular interface abnormalities
- Being tested
- ocular coherence tomography
- Keywords
- unrecognized condition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ocular coherence tomographyDevice
imaging by ocular coherence tomography
What is being measured
The primary outcome is the main question the study is designed to answer.
measuring visual acuity by snellen chart
measuring visual acuity by snellen chart full ophthalmic examination dilating the pupil by mydriatic 1-tropicamide1%drop phenylephrine 2.5%eye drop fundus photography is achived by using TRC 8PLUS TOPCON MEDICAL System,Inc OCT imaging is achived by using Spectral domain OCT (hiedelbrge)
Measured: two hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Sep 2018
- Study start1 Feb 2019 (estimated)
- Primary completion1 Feb 2020 (estimated)
- Study completion1 Mar 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for on Vitreomacular Interface Abnormalities in Diabetic RetinopathyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, seham dahy, Assiut University
- Investigators
- abdalnaser kamil, Study chair, Asiut university
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03686436
- Sponsor's protocol ID
- seham dahy
- Status last verified
- Jan 2019
- First submitted
- 25 Sep 2018
- Last updated
- 17 Jan 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: all IPD data will be shared include the age of the patient his heath condition an all information regarding his vision and ophthalmic data and fudus photoes and OCT imaging
Publications
1- Agarwal D, Gelman R, Ponce CP, Stevenson W, and . Christoforidis J B the vitreo macular interface abnormalities in diabetic retinopathy . review. . journal of ophthalmology . 2015. 2- Bottós J, Elizalde J, Arevalo JF, Rodrigues EB, Maia M. Vitreomacular traction syndrome. J Ophthalmic Vis Res 2012 3- Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013 4- konsantanidis L , Wolfensberger TJ .cystoid macular edema and vitreomacular traction . a review .2015 5- Ryan SJ, Puliafito CA, Davis JL, Parel JM, Milne P. Retina. 4th ed. Philadelphia, PA:Elsevier Mosby; 2006. 6- Chandra A, Charteris DG, Yorston D. Posturing after macular hole surgery: a review. Ophthalmologica 2011
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vitreomacular Interface Abnormalities Indiabetic Retinopathy Using Ocular Coherence Tomography
- ClinicalTrials.gov ID
- NCT03686436
- Acronym / sponsor ID
- seham dahy
- Keywords
- unrecognized condition
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Feb 2019 (estimated)
- Primary completion
- 1 Feb 2020 (estimated)
- Study completion
- 1 Mar 2021 (estimated)
- First posted
- 27 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
to evaluate vitreomacular interface abnormalities in diabetic retinopathy by using Ocular Coherence Tomography (OCT)
Detailed description
Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness .DR can be complicated by scar tissue formation, macular edema tractional retinal detachment. Optical coherence tomography has found patient with DR has diffuse retinal thickening , cystoid macular edema ,posterior hayaloid traction ,tractional retinal detachment.
The VMI in patient with DR can influence the emergence ,progression ,and treatment of DR.
The role of posterior hyaloid and vitreous on viteromacular interface abnormalities The anomalous separation of vitreous cortex from ILM can lead to abnormal vitreomacular interface. This separation can happen when liquefaction occur faster than detachment of the vitreous cortex or when an abnormal adhesion of the vitreous cortex to the ILM occur.
The VMI abnormalities in DR include I. Vitreomacular adhesion The International Vitreomacular Traction Study group has defined the vitremacular adhesion as specific stage of vitreous separation when partial detachment of the vitreous in perifoveal area has occurred without any abnormalities to the retinal contour.
II. Vitreomacular traction There is abnormal vitreous adhesion, there can be excessive traction on the macula from the vitreous that change the contour of foveal surface. By OCT any distortion of foveal contour together with partial posterior vitreous detachment is considered vitreomacular traction . In accordance with the International Vitreomacular Traction Study Group definition vitreomacular traction can be classified as focal or broad based on horizontal area of adhesion.
III. Cystoid macular edema The vitreous has been implicated as a cause of macular edema via mechanical and physiologic mechanisms.One of the most constructive hypothesis on how vitreomacular traction may result in macular edema was given by Schubert in 1989,and was summarized by Bringmann and Wiedmann Vitro retinal traction can also exert forces at the level of retinal pigment epithelium ,which can eventually result in morphological retinal pigment epithelial changes .
IV. Epiretinal membrane The epiretinal membrane is a cellular proliferation that creates a semi translucent, fibrocellular proliferation on the surface of the inner retina. Because epiretinal membrane contain contractile cellular elements they can be associated with retinal folding and macular thickening thereby leading to decreased visual acuity, metamorphopsia, monocular diplopia .
- Full thickness hole Is a full thickness defect in the fovea, include the complete interruption of all retinal layers from the ILM to the retinal pigment epithelium. antero posterior traction, secondary to abnormal attachment at the fovea, and tangential contraction of the perifoveal vitreous cortex may be responsible for the development of the macular hole.
VI. Lamellar holes These include an irregular foveal contour, a defect or break in the inner fovea, a splitting of the inner and outer retina , lack of a full thickness foveal defect, and intact photo receptors.
VII. Macular pseudo hole By OCT the pseudo hole has no loss of retinal tissue. They have invaginated or heaped foveal edge, an epiretinal membrane with a central opening ,and a steep macular contour to the central fovea .the steep foveal contour creates the appearance of hole, even though there is no loss of retinal tissue.
Aim of work Primary outcome : To evaluate the changes in vitreomacular interface in diabetic retinopathy by using Spectral Domain Ocular Coherence Tomography ( SD OCT) Secondary outcome : To evaluate other macular changes in Spectral Domain Ocular Coherence Tomography ( SD OCT) in diabetic patient with vitreomacular interface abnormalities
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 12 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- diabetic male and female patient with age between 12 and 70 years who live in Asiut city
Key inclusion criteria (1 listed)
- diabetic patient with or without treatment and with or without evidence of vitreomacular traction on clinical examination
Key exclusion criteria (2 listed)
- diabetic patient with unclear media as dense cataract,
- vitreous Hemorrhage and corneal opacity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ocular coherence tomographyimaging by ocular coherence tomography | Device | – |
Primary outcome
measuring visual acuity by snellen chart
Time frame: two hours
measuring visual acuity by snellen chart full ophthalmic examination dilating the pupil by mydriatic 1-tropicamide1%drop phenylephrine 2.5%eye drop fundus photography is achived by using TRC 8PLUS TOPCON MEDICAL System,Inc OCT imaging is achived by using Spectral domain OCT (hiedelbrge)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2019.
- Results publication1- Agarwal D, Gelman R, Ponce CP, Stevenson W, and . Christoforidis J B the vitreo macular interface abnormalities in diabetic retinopathy . review. . journal of ophthalmology . 2015. 2- Bottós J, Elizalde J, Arevalo JF, Rodrigues EB, Maia M. Vitreomacular traction syndrome. J Ophthalmic Vis Res 2012 3- Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013 4- konsantanidis L , Wolfensberger TJ .cystoid macular edema and vitreomacular traction . a review .2015 5- Ryan SJ, Puliafito CA, Davis JL, Parel JM, Milne P. Retina. 4th ed. Philadelphia, PA:Elsevier Mosby; 2006. 6- Chandra A, Charteris DG, Yorston D. Posturing after macular hole surgery: a review. Ophthalmologica 2011
- Individual participant dataSharing planned: Yes. all IPD data will be shared include the age of the patient his heath condition an all information regarding his vision and ophthalmic data and fudus photoes and OCT imaging
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
sharaf mohamed contact
abdalnaser kamil study chair
Asiut university
Questions about this trial
What is this clinical trial studying?
An observational study of on Vitreomacular Interface Abnormalities in Diabetic Retinopathy, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact dahy seham, M.B.B.CH (+2001012060672, dahyseham@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
measuring visual acuity by snellen chart (time frame: two hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03686436, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2019; AzTrials last refreshed its copy on 27 Oct 2026.